ONODERA GT Pharma Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
47
- Latest Deal Type
-
Series A
- Investors
-
7
ONODERA GT Pharma General Information
Description
Developer of gene therapy intended to carry out research and development on neurodegenerative diseases. The company's drugs specialize in developing gene therapies for refractory diseases primarily focusing on Parkinson's disease, amyotrophic lateral sclerosis (ALS), and Alzheimer's disease, enabling patients to get therapies while suffering from refractory illnesses.
Contact Information
Website
www.onodera-gtp.comCorporate Office
- 25-22, Tonomachi 3-chome, Kawasaki-ku
- Kawasaki-shi
- Kanagawa, 210-0821
- Japan
Corporate Office
- 25-22, Tonomachi 3-chome, Kawasaki-ku
- Kawasaki-shi
- Kanagawa, 210-0821
- Japan
ONODERA GT Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC (Series A) | 31-Oct-2022 | Completed | Clinical Trials - Phase 2 | |||
| 4. Later Stage VC | 24-Jun-2020 | Completed | Pre-Clinical Trials | |||
| 3. Later Stage VC (Series A) | 24-Dec-2019 | Completed | Pre-Clinical Trials | |||
| 2. Secondary Transaction - Private | 19-Feb-2016 | $163K | Cancelled | Pre-Clinical Trials | ||
| 1. Corporate | Completed | Pre-Clinical Trials |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
ONODERA GT Pharma Comparisons
Industry
Financing
Details
ONODERA GT Pharma Competitors (5)
One of ONODERA GT Pharma’s 5 competitors is Regenxbio, a Formerly VC-backed company based in Rockville, MD.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Regenxbio | Formerly VC-backed | Rockville, MD | ||||
| uniQure | Formerly VC-backed | Amsterdam, Netherlands | ||||
| Sarepta Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Rocket Pharmaceuticals | Formerly VC-backed | Cranbury, NJ | ||||
| BioMarin Pharmaceutical | Formerly PE-Backed | San Rafael, CA |
ONODERA GT Pharma Patents
ONODERA GT Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4328313-A1 | Adeno-associated virus virion for treating ornithine transcarbamylase deficiency | Pending | 21-Apr-2021 | ||
| EP-4328313-A4 | Adeno-associated virus virion for treating ornithine transcarbamylase deficiency | Pending | 21-Apr-2021 | ||
| US-20250339480-A1 | Adeno-associated virus virion for treating ornithine transcarbamylase deficiency | Pending | 21-Apr-2021 | ||
| WO-2022224372-A1 | Adeno-associated virus virion for treating ornithine transcarbamylase deficiency | Inactive | 21-Apr-2021 | ||
| JP-2021097617-A | Adeno-associated virus virion for treatment of ornithine transcarbamylase deficiency | Pending | 20-Dec-2019 |
ONODERA GT Pharma Signals
ONODERA GT Pharma Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Healthcare Innovation | Venture Capital | Minority | ||
| PTC Therapeutics | Corporation | Minority | ||
| Sekisui Chemical | Corporation | Minority | ||
| Alfresa Holdings | Corporation | Minority | ||
| Environment Friendly Holdings | Holding Company | Minority |
ONODERA GT Pharma Investments (1)
ONODERA GT Pharma’s most recent deal was a Joint Venture with Adeno-Associated Virus Gene Therapies (Agilis Biotherapeutics & Gene Therapy Research Institution). The deal was made on 02-Aug-2017.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Adeno-Associated Virus Gene Therapies (Agilis Biotherapeutics & Gene Therapy Research Institution) | 02-Aug-2017 | Joint Venture | Drug Discovery |
ONODERA GT Pharma FAQs
-
When was ONODERA GT Pharma founded?
ONODERA GT Pharma was founded in 2014.
-
Where is ONODERA GT Pharma headquartered?
ONODERA GT Pharma is headquartered in Kanagawa, Japan.
-
What is the size of ONODERA GT Pharma?
ONODERA GT Pharma has 47 total employees.
-
What industry is ONODERA GT Pharma in?
ONODERA GT Pharma’s primary industry is Biotechnology.
-
Is ONODERA GT Pharma a private or public company?
ONODERA GT Pharma is a Private company.
-
What is the current valuation of ONODERA GT Pharma?
The current valuation of ONODERA GT Pharma is .
-
What is ONODERA GT Pharma’s current revenue?
The current revenue for ONODERA GT Pharma is .
-
Who are ONODERA GT Pharma’s investors?
Healthcare Innovation, PTC Therapeutics, Sekisui Chemical, Alfresa Holdings, and Environment Friendly Holdings are 5 of 7 investors who have invested in ONODERA GT Pharma.
-
Who are ONODERA GT Pharma’s competitors?
Regenxbio, uniQure, Sarepta Therapeutics, Rocket Pharmaceuticals, and BioMarin Pharmaceutical are competitors of ONODERA GT Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process